PMID- 29496758
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20190506
IS  - 1399-3003 (Electronic)
IS  - 0903-1936 (Linking)
VI  - 51
IP  - 4
DP  - 2018 Apr
TI  - Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial 
      pneumonia and interstitial pneumonia with autoimmune features (IPAF).
LID - 1702519 [pii]
LID - 10.1183/13993003.02519-2017 [doi]
FAU - Wiertz, Ivo A
AU  - Wiertz IA
AD  - Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius 
      Hospital, Nieuwegein, The Netherlands.
FAU - van Moorsel, Coline H M
AU  - van Moorsel CHM
AD  - Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius 
      Hospital, Nieuwegein, The Netherlands.
AD  - Division of Heart and Lungs, University Medical Centre Utrecht, The Netherlands.
FAU - Vorselaars, Adriane D M
AU  - Vorselaars ADM
AD  - Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius 
      Hospital, Nieuwegein, The Netherlands.
FAU - Quanjel, Marian J R
AU  - Quanjel MJR
AD  - Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius 
      Hospital, Nieuwegein, The Netherlands.
FAU - Grutters, Jan C
AU  - Grutters JC
AD  - Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius 
      Hospital, Nieuwegein, The Netherlands.
AD  - Division of Heart and Lungs, University Medical Centre Utrecht, The Netherlands.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20180419
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Adrenal Cortex Hormones)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adrenal Cortex Hormones/administration & dosage
MH  - Cyclophosphamide/*administration & dosage
MH  - Humans
MH  - Idiopathic Interstitial Pneumonias/*drug therapy
MH  - Lung/*physiopathology
MH  - Retrospective Studies
MH  - Vital Capacity
COIS- Conflict of interest: I.A. Wiertz reports that this study is part of a research 
      project (842002003) funded by ZonMw. He has received grants from 
      Boehringer-Ingelheim (50% of travel payment to attend the WASOG 2015 
      international congress), outside the submitted work. Conflict of interest: J.C. 
      Grutters reports grants from Boehringer-Ingelheim (two advisory board fees of 
      <1000 EUR; and four 50% of travel payments to attend international congresses 
      (ATS 2016, ATS 2015, WASOG 2015 and ATS 2014)), outside the submitted work.
EDAT- 2018/03/03 06:00
MHDA- 2019/05/07 06:00
CRDT- 2018/03/03 06:00
PHST- 2017/12/05 00:00 [received]
PHST- 2018/02/17 00:00 [accepted]
PHST- 2018/03/03 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
PHST- 2018/03/03 06:00 [entrez]
AID - 13993003.02519-2017 [pii]
AID - 10.1183/13993003.02519-2017 [doi]
PST - epublish
SO  - Eur Respir J. 2018 Apr 19;51(4):1702519. doi: 10.1183/13993003.02519-2017. Print 
      2018 Apr.